A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

StatusTerminated
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Business Reasons Show 4 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Final enrollment: 30 participants (planned 70)
    • Primary and study completion dates changed from estimate of Sep 30, 2026 to Sep 29, 2026
    • Eligibility criteria expanded, about 23 words
  2. Primary and study completion pushed from Jul 31, 2026 to Sep 30, 2026v30
  3. Re-verified, no change to tracked fieldsv29
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 8 of 8 sites
    v28
  5. Primary and study completion dates: May 29, 2026 to Jul 31, 2026v27
Show 25 earlier versionsHide 25 earlier versions
  1. Study sites revised (8)v26
  2. Re-verified, no change to tracked fieldsv25
  3. Site details revised at 1 of 8 sitesv24
  4. 6 versions Re-verified since Sep 1, 2023, no change to tracked fieldsv18-v23
  5. Study sites: 7 to 8v17
  6. Re-verified, no change to tracked fieldsv16
  7. Site details revised at 1 of 7 sitesv15
  8. 3 versions Re-verified since Mar 8, 2023, no change to tracked fieldsv12-v14
  9. Primary and study completion dates: Jan 19, 2026 to May 29, 2026
    • Site details revised at 1 of 7 sites
    v11
  10. Site details revised at 1 of 7 sitesv10
  11. Site details revised at 1 of 7 sitesv9
  12. Site details revised at 1 of 7 sitesv8
  13. Site details revised at 1 of 7 sitesv7
  14. Site details revised at 1 of 7 sitesv6
  15. Study sites: 6 to 7v5
  16. Study sites: 5 to 6v4
  17. Study sites: 3 to 5v3
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Jun 23, 2022 to Jun 16, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
412 trials monitored
See 25 trials at risk
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
Trial Details
NCT Number NCT05382325
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Advanced or Metastatic Solid Tumors
Related terms Parkinson Disease 4, Autosomal Dominant Lewy Body
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov